The pandemic of 2020 affected how we do our science, how we live our lives, how we interrelate and how we advance exosome medicine in a world that seems to be standing still. As a thank you to all of our staff, their families, our peers, our investors and our collaborators for your belief, hard […]
Producing EVs at the Clinical Scale On November 11, we presented at the Exosome Based Therapeutic Development Digital Summit. At this key exosome industry event, we had the opportunity to highlight our LEAP technology, the team’s accomplishments and our commitment to collaboration to advance the development of all exosome therapeutics. Our Chief Commercial Officer, Dr […]
“The biggest problem is to purify the EVs from their source and to eliminate the contaminants, and not damage the EVs,” says Managing Director and founder Dr Ian Dixon. One of the great things about our LEAP technology and process is that it is scalable. You can read the full Stockhead article here.
Chief Commercial Officer, Dr Chris Baldwin, will present to the Exosome Based Therapeutic Development Digital Summit on 11 November (9:00 AM US Eastern Time, 1.00 AM AEDT), the first day of the two-day event. You can find the slide deck here.
Our science is too important to leave to just the scientists. On November 5, Dr Balarka Banerjee and Dr Kartini Asari explained some of the advances Exopharm is making. This science update forms part of our ‘Behind the Scenes’ webinar series. Stem Cells: Exosome Factories Dr. Balarka Banerjee, Cell Development Manager Exopharm’s unique LEAP […]
“With a successful outcome from PLEXOVAL II, Exopharm will be well-positioned to initiate Phase 2 studies with off-the-shelf Plexaris and Phase 1 studies with our mesenchymal stem cell EV product Cevaris,” said Angus Tester, Head of Product Evaluation. You can read the full Stockhead article here.
Yesterday, Chief Commercial Officer Chris Baldwin sat down with Stockhead’s resident health and biotech expert Tim Boreham for the latest episode of The Health Kick Podcast. They discuss the potential of exosomes to transform healthcare, and our journey to commercialising our exosome therapeutics. Click below to listen. You can find the full post here.
How mRNA vaccines could defeat the novel coronavirus Head of Innovation Andy Coley spoke with Stockhead about the potential of mRNA for fighting COVID-19, including Moderna’s vaccine candidate and Fortrexo, our engineered EV approach. You can find the full article here.
ShareCafe’s “Hidden Gems” Webinar 18 Sept 2020 Chief Commercial Officer Chris Baldwin provides updates on Exopharm’s Technology and Naive EV programs, including the addition of Alison Mew to the senior leadership and the progress on Exopharm’s second clinical trial.
Behind the Scenes with our Scientists Recently, there has been a variety of updates about the company’s business progress and accomplishments. This webinar provided a closer look at some of science and technology behind our most recent advances, Fortrexo CoV™ and Exoria™. RNAi’s to Stop Coronavirus Dr Karen Holden, Head of Translation Exopharm has […]
Exopharm has announced a placement of shares to raise $10 million. Canary Capital, the manager of the placement, and its directors have elected to take the majority of their fees in shares. “In Exopharm, Canary has identified an Australian company with proprietary technology that can compete on the world stage”, says Paul Hart, Executive Director […]
“As a serial biotechnology entrepreneur, Dr Dixon doesn’t just develop technologies or products – he wants to build long-lasting businesses based upon big ideas.” Written by our Chief Commercial Officer Chris Baldwin, this Sharecafe article explains Dr Dixon’s big idea back in 2013 and how it led to the foundation of Exopharm. Today, Exopharm is […]
Exopharm CCO Dr Chris Baldwin gives a shareholder update on the ‘Morning Twilight Briefing’ webinar series hosted by Monsoon Communications. Chris discusses Exopharm’s key development areas and provides an overview of the company’s engineered EV technology.
Biotech Daily’s Tim Boreham likes Exopharm’s focus: “Given the scientifically complex nature of Exopharm’s quest to develop exosomes into therapeutics, it’s good to see that founder and chief executive Ian Dixon hasn’t lost sight of the commercial basics.” Read the full article here.
MST Access, a division of MST Financial which provides institutional-grade research for small and medium cap companies, has initiated coverage of Exopharm Ltd (ASX: EX1). Read the full report here.
Their Curiosity and Enthusiasm are Infectious… Recently Chief Commercial Officer Chris Baldwin sat down with StockPal to discuss the CEO mindset. Read Chris’ thoughts on Exopharm, measuring success, and the future of exosome medicines. Read the full article on Stockpal Asia.
BD Team Welcomes Partners The Business Development team is excited to be participating in the virtual “Bio Digital Partnering Convention 2020.” With over 30 meetings with potential business partners from around the globe already planned, they are eager to find partners to help us in our mission to bring exosome medicines to the world. Other […]
Exopharm Webinar May 2020 – Our Strategic Response to COVID-19 Exopharm updates the public on its recent progress and activities. Hosted by Jason Watson, Chair of Exopharm, Ian Dixon (CEO), Gregor Lichtfuss (COO) and Chris Baldwin (CCO) discuss how COVID-19 has affected operations and strategies. The application of Exopharm’s engineered exosome program, Fortrexo, is discussed, […]
Dr. Ian Dixon: Bio Insights Exosomes at scale as next-generation cell free medicines: Fact and Fiction In 2020, exosomes (also known as extracellular vesicles [EVs]) are emerging from academic laboratories and into biotechnology company led clinical trials. But this progress has, until now, been held back by the absence of a robust, scalable and proprietary […]
Early studies suggest regenerative medicine could halt or even reverse the onset of age-related sensory impairment Gradually losing the ability to experience and enjoy the world around you can be one of the most debilitating aspects of ageing. Vision impairment, hearing loss and other sensory disabilities affecting smell, taste or touch are among the […]
Exosomes: Nanoparticles full of Surprises If the past few years of exosome research has taught us anything about these tiny biomolecule-filled parcels, it is that ‘what do exosomes do?’ is the wrong question to ask. In the context of cell to cell communication, ‘what don’t exosomes do’ seems to be a better starting point. As […]
Destination: Exosomes A growing number of stem cell companies are seeing the light and shifting their focus to exosome products. An interesting mixture of companies are lining up to follow Exopharm’s lead and begin human clinical trials of therapeutic exosome candidates. At least three exosome companies are aiming to start clinical trials during 2020, and […]
Exopharm backs regulatory crackdown on unapproved exosome products A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting the health dangers of unapproved products peddled by clinics that are openly flouting the rules. In a public safety notification released on December 6, the FDA highlighted reports […]
What Are Exosomes and Why Are Exosomes Important? What Are Exosomes? Definition of Exosomes Exosomes are defined as nanometre-sized vesicles, being packages of biomolecules ranging from 40-150 nanometres in size that are released by virtually every cell type in the body. Once thought to be a kind of refuse disposal system for cells, exosomes are […]
The New Science of Aging: Winding Back the Body Clock Human age reversal has jumped from pure science fiction to research reality. Until very recently, the idea of age reversal and rejuvenation in humans was not a topic discussed in serious scientific circles. The idea was, at best, highly speculative. At worst it was the […]
Turning Back the Body Clock With Exosomes New research reinforces the possibility that exosomes derived from stem cells can bring the body back into a more healthful, youthful state. Two recent publications highlight the growing relevance of exosomes to aging. One report highlights that the aging of humans is associated with an accelerating decline in […]
The Potential of Exosomes Exosomes are moving toward clinical use in numerous and diverse ways There are around 37 trillion cells in a human body—and like any collective of diverse individuals they rely upon constant communication to work together. Just over a decade ago a research team in Sweden published in Nature Cell Biology a […]
Understanding regenerative medicine’s point-of-difference Companies testing exosome-based therapies are developing completely new ways to tackle the wide array of medical conditions that afflict us in old age. Exosomes from stem cells are an emerging regenerative medicine that could disrupt the way age-related degeneration is treated, including problems such as cardiovascular disease, neurodegeneration, osteoporosis and erectile […]
Exopharm: Preparation, Demonstration and Reward As a biotech stock, order or to maximise the financial returns from our technologies and products there are a number of aspects to the business of Exopharm. As a headline, we see ourselves as world leaders in a new type of regenerative medicine – harnessing exosomes as the ‘secret sauce’ […]
Exosome Therapeutic Research Emerging from the Lab The more we study these naturally produced packets of biomolecules, the more therapeutic use they seem to lend themselves to be. Exosomes, pro-healing nanoparticles found naturally in the body, are a new potential paradigm in healthcare that could assist in every step we take through life. In their […]
Exosomes vs Stem Cells: Exosomes as the Next Big Thing after Stem Cell Therapy The exosomes (or ‘extracellular vesicles’) released by stem cells may be the disruptive therapy for tackling age-related diseases doctors and patients have been waiting for. Despite over a decade and a half of hope and hype, stem cell therapy has failed […]
Exopharm: Reducing Risk. Making Drugs by Purifying not Synthesising In this note to shareholders and potential investors, the company outlines Exopharm’s risk-profile and how the business of Exopharm compares with other types of listed biotechnology companies. Exopharm: Context Exopharm is an ASX listed regenerative medicine company focused on bringing exosomes into clinical use as a […]
Exosomes (or extra cellular vesicles) are a new way to treat medical conditions including health span related medical problems. Exosomes are showing a great deal of promise in the Biotech industry as the future of regenerative medicine. What Are Exosomes? Exosomes are tiny packages of biomolecules released by cells1. They range between 40 and 200 […]
Biotech and Exosome Investment Growth Recent financial transactions highlight increasing biotech investment activity in the field of exosomes and extracellular vesicles. These naturally occurring packets of biomolecules could represent a new paradigm in healthcare. Exopharm Limited (ASX-EX1) is one of a small number of Australian biotech stocks currently attracting investors in regenerative medicine, and its […]
The Critical Bottleneck of Exosome Isolation and the Power of Exopharm’s LEAP Technology Why Exopharm is poised to be a leader in the field of therapeutic exosomes. Exosomes (also known as extracellular vesicles or EVs) from stem cells are poised to become a new form of regenerative medicine – described by some as the ‘secret […]
Regenerative Medicine: Questions and Answers What is regenerative medicine? Regenerative medicine is a term used to cover different ways scientists can harness the body’s own regenerative capabilities. What are some examples of regenerative medicines? An old example is blood. Blood (or blood plasma) from donors is used routinely in hospitals if the patient needs more […]
Meet the Exosomes Exactly a decade ago, a seminal paper revealed the role exosomes play in the body. Read on for Exopharm’s guide on what exosomes are, and why they’re beginning to create a buzz in medical circles. Human cells are a gregarious bunch – otherwise we would fall apart. They continually message each other, […]
Exosomes Linking Obesity and Diabetes Exosomes from lean individuals can reverse the symptoms of diabetes associated with obesity, a new animal study shows Inflammatory exosomes are the missing link by which obesity causes type 2 diabetes, researchers from the University of California San Diego have shown. The discovery could lead to earlier diabetes diagnosis and […]
Could exosome therapy help athletes recover from injury faster – and help the rest of us by mimicking the whole-body benefits of exercise? Some people don’t get enough physical exercise – but others suffer from too much activity, injury and over-training. Many sports players are set to benefit from the dawning era of exosome medicine. […]
Exosomes as Drug Delivery Vehicles: Natural Nano-bio-drones In the not too distant future, click ‘buy’ on an internet shopping site and an autonomous drone will be dispatched to carry your new goods directly to your doorstop. For now, drone home-delivery is still science fiction – but inside the body, targeted autonomous delivery of packages is […]
